CD8A and neoplasm: Blocking CD27 signaling in combination with anti-PD-1 therapy has been shown to increase the number of CD8+ T cells within tumors and improve the CD8+ T cell/Treg ratio, thereby enhancing the anti-tumor efficacy (74).